Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients.
Ankylosing spondylitis
Biologics
Bone density
Osteoporosis
Peripheral quantitative computed tomography
Rheumatoid arthritis
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
23 Sep 2021
23 Sep 2021
Historique:
received:
08
04
2021
accepted:
11
09
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with osteoporosis. There have not been many peripheral quantitative computed tomography (QCT) studies in patients receiving biologics. We assessed volumetric and areal bone mineral density (BMD) by forearm QCT and dual-energy X-ray absorptiometry (DXA), respectively in addition to laboratory biomarkers in these arthritides. Forty RA and AS patients treated with either etanercept (ETN) or certolizumab pegol (CZP) were undergoing follow-ups for one year. Volumetric and areal BMD, as well as parathyroid hormone (PTH), osteocalcin, RANKL, 25-hydroxyvitamin D (VITD), P1NP, CTX, sclerostin (SOST), Dickkopf 1 (DKK-1) and cathepsin K (CATHK) were determined. We did not observe any further bone loss during the 12-month treatment period. Volumetric and areal BMD showed significant correlations with each other (p<0.017 after Bonferroni's correction). Trabecular QCT BMD at baseline (p=0.015) and cortical QCT BMD after 12 months (p=0.005) were inversely determined by disease activity at baseline in the full cohort. Trabecular QCT BMD at baseline also correlated with CTX (p=0.011). In RA, CRP negatively (p=0.014), while SOST positively (p=0.013) correlated with different QCT parameters. In AS, RANKL at baseline (p=0.014) and after 12 months (p=0.007) correlated with cortical QCT BMD. In the full cohort, 12-month change in QTRABBMD was related to TNF inhibition together with elevated VITD-0 levels (p=0.031). Treatment and lower CATHK correlated with QCORTBMD changes (p=0.006). In RA, TNF inhibition together with VITD-0 (p<0.01) or CATHK-0 (p=0.002), while in AS, treatment and RANKL-0 (p<0.05) determined one-year changes in QCT BMD. BMD as determined by QCT did not change over one year of anti-TNF treatment. Disease activity, CATHK, RANKL and VITD may be associated with the effects of anti-TNF treatment on QCT BMD changes. RA and AS may differ in this respect.
Identifiants
pubmed: 34556105
doi: 10.1186/s12891-021-04708-5
pii: 10.1186/s12891-021-04708-5
pmc: PMC8461899
doi:
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
817Informations de copyright
© 2021. The Author(s).
Références
J Exp Med. 2000 Jan 17;191(2):275-86
pubmed: 10637272
Semin Arthritis Rheum. 2010 Apr;39(5):369-83
pubmed: 19095294
Arthritis Care Res (Hoboken). 2017 Aug;69(8):1156-1163
pubmed: 27768831
Rheumatol Int. 1991;11(1):41-4
pubmed: 1866572
Arthritis Rheum. 1992 Sep;35(9):1062-7
pubmed: 1418022
BMC Musculoskelet Disord. 2013 Dec 24;14:367
pubmed: 24364867
Calcif Tissue Int. 2012 Nov;91(5):343-55
pubmed: 22945690
Drugs Aging. 2019 Dec;36(12):1061-1072
pubmed: 31541358
Ann Rheum Dis. 1998 Jun;57(6):325-7
pubmed: 9771204
Nat Rev Rheumatol. 2009 Dec;5(12):667-76
pubmed: 19884898
Ann Rheum Dis. 2016 Jan;75(1):3-15
pubmed: 25969430
J Rheumatol. 2016 Oct;43(10):1935-1940
pubmed: 27698108
Autoimmun Rev. 2017 Mar;16(3):313-320
pubmed: 28159704
Arthritis Res Ther. 2013;15(3):R62
pubmed: 23710573
Ann Rheum Dis. 2006 Nov;65(11):1495-9
pubmed: 16606653
Arthritis Care Res (Hoboken). 2011 Mar;63(3):383-9
pubmed: 21080350
Arthritis Res Ther. 2017 Oct 4;19(1):222
pubmed: 28978352
Orthop Clin North Am. 1985 Jul;16(3):557-68
pubmed: 3892413
Semin Nucl Med. 1987 Oct;17(4):316-33
pubmed: 3317846
Rheumatology (Oxford). 2013 Mar;52(3):547-53
pubmed: 23221326
BMC Musculoskelet Disord. 2014 Sep 02;15:289
pubmed: 25182527
J Rheumatol. 2013 Apr;40(4):408-16
pubmed: 23418386
Clin Rheumatol. 2020 Jan;39(1):167-175
pubmed: 31522318
Curr Rheumatol Rep. 2010 Oct;12(5):332-6
pubmed: 20680529
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
BMC Musculoskelet Disord. 2011 May 31;12:121
pubmed: 21627836
J Rheumatol. 2016 Oct;43(10):1911-1913
pubmed: 27698105
Nat Clin Pract Rheumatol. 2005 Nov;1(1):47-54
pubmed: 16932627
J Clin Invest. 2000 Dec;106(12):1481-8
pubmed: 11120755
Curr Rheumatol Rep. 2012 Jun;14(3):231-7
pubmed: 22527950
Ann Rheum Dis. 2018 Jan;77(1):3-17
pubmed: 28684559
J Clin Densitom. 2008 Jan-Mar;11(1):123-62
pubmed: 18442757
Osteoporos Int. 2017 Apr;28(4):1271-1277
pubmed: 27942777
Bone. 2019 May;122:8-13
pubmed: 30708186